Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adapalene Gel Clear all
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel

NCT01522456
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Epiduo Gel, Retin-A Micro Microsphere 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

NCT02932267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.3% / BPO 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

NCT00647556
View directory record Official record
Conditions
Photoaging
Interventions
adapalene gel, 0.3%, tretinoin 0.05% emollient cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

NCT06336603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 3, 2026, 8:58 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

NCT01485367
View directory record Official record
Conditions
Senile Purpura
Interventions
adapalene gel 0.3%
Drug
Lead sponsor
Multispecialty Aesthetic Clinical Research Organization
Other
Eligibility
52 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Woodland Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

NCT01951417
View directory record Official record
Conditions
Acne
Interventions
Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Boynton Beach, Florida • Nashville, Tennessee • Carrollton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

NCT00964223
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Rockville, Maryland • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

NCT01213199
View directory record Official record
Conditions
Acne Scars
Interventions
Adapalene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

NCT02651220
View directory record Official record
Conditions
Acne
Interventions
Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care
Drug · Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

NCT00687908
View directory record Official record
Conditions
Acne
Interventions
Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

NCT00907101
View directory record Official record
Conditions
P Acnes Colonization
Interventions
Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Active, not recruiting Early Phase 1 Interventional

Experience With Topical Acne Treatment

NCT05582434
View directory record Official record
Conditions
Acne
Interventions
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

NCT00660985
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Withdrawn Phase 3 Interventional

MC RCT - BPO vs Adapalene

NCT05536882
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Benzoyl peroxide, Adapalene Gel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 14 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 3, 2026, 8:58 PM EDT
Recruiting Phase 4 Interventional

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00421993
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene, Benzoyl Peroxide, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

A Treatment for Severe Inflammatory Acne Subjects

NCT02899000
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel, Oral doxycycline hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 3, 2026, 8:58 PM EDT